Literature DB >> 25901437

Adjuvant ovarian suppression in premenopausal breast cancer.

Prudence A Francis, Meredith M Regan, Gini F Fleming.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25901437     DOI： 10.1056/NEJMc1502618

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  14 in total

1.  What Can We Learn From Menstrual Patterns After Treatment for HER2-Positive Breast Cancer?

Authors:  Elizabeth Cathcart-Rake; Kelly C Gast; Kathryn J Ruddy
Journal:  J Natl Cancer Inst       Date:  2019-01-01       Impact factor: 13.506

2.  Embryonic transcription factor SOX9 drives breast cancer endocrine resistance.

Authors:  Rinath Jeselsohn; MacIntosh Cornwell; Matthew Pun; Gilles Buchwalter; Mai Nguyen; Clyde Bango; Ying Huang; Yanan Kuang; Cloud Paweletz; Xiaoyong Fu; Agostina Nardone; Carmine De Angelis; Simone Detre; Andrew Dodson; Hisham Mohammed; Jason S Carroll; Michaela Bowden; Prakash Rao; Henry W Long; Fugen Li; Mitchell Dowsett; Rachel Schiff; Myles Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-15       Impact factor: 11.205

Review 3.  Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers.

Authors:  Kelly C Gast; Paul V Viscuse; Somaira Nowsheen; Tufia C Haddad; Robert W Mutter; Andrea E Wahner Hendrickson; Fergus J Couch; Kathryn J Ruddy
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-01

4.  Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.

Authors:  Meritxell Bellet; Kathryn P Gray; Prudence A Francis; István Láng; Eva Ciruelos; Ana Lluch; Miguel Angel Climent; Gustavo Catalán; Antoni Avella; Uriel Bohn; Antonio González-Martin; Roser Ferrer; Roberto Catalán; Analía Azaro; Agnita Rajasekaran; Josefa Morales; Josep Vázquez; Gini F Fleming; Karen N Price; Meredith M Regan
Journal:  J Clin Oncol       Date:  2016-01-04       Impact factor: 44.544

Review 5.  Evaluating the Survival Benefit Following Ovarian Function Suppression in Premenopausal Patients with Hormone Receptor Positive Early Breast Cancer.

Authors:  Lin Qiu; Fangmeng Fu; Meng Huang; Yuxiang Lin; Yazhen Chen; Minyan Chen; Chuan Wang
Journal:  Sci Rep       Date:  2016-05-27       Impact factor: 4.379

6.  Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm.

Authors:  Raquel E Reinbolt; Stephen Sonis; Cynthia D Timmers; Juan Luis Fernández-Martínez; Ana Cernea; Enrique J de Andrés-Galiana; Sepehr Hashemi; Karin Miller; Robert Pilarski; Maryam B Lustberg
Journal:  Cancer Med       Date:  2017-11-23       Impact factor: 4.452

7.  Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers.

Authors:  Florin-Andrei Taran; Andreas Schneeweiss; Michael P Lux; Wolfgang Janni; Andreas D Hartkopf; Naiba Nabieva; Friedrich Overkamp; Hans-Christian Kolberg; Peyman Hadji; Hans Tesch; Achim Wöckel; Johannes Ettl; Diana Lüftner; Markus Wallwiener; Volkmar Müller; Matthias W Beckmann; Erik Belleville; Diethelm Wallwiener; Sara Y Brucker; Peter A Fasching; Tanja N Fehm; Florian Schütz
Journal:  Geburtshilfe Frauenheilkd       Date:  2018-03-21       Impact factor: 2.915

8.  Adherence and Persistence to Adjuvant Hormonal Therapy in Early-Stage Breast Cancer Patients: A Population-Based Retrospective Cohort Study in Israel.

Authors:  Tal Sella; Gabriel Chodick
Journal:  Breast Care (Basel)       Date:  2019-05-29       Impact factor: 2.860

9.  Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States.

Authors:  Bobby Daly; Olufunmilayo I Olopade; Ningqi Hou; Katharine Yao; David J Winchester; Dezheng Huo
Journal:  JAMA Oncol       Date:  2017-07-01       Impact factor: 31.777

10.  Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node-Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer.

Authors:  Guiyun Sohn; Sei Hyun Ahn; Hee Jeong Kim; Byung-Ho Son; Jong Won Lee; Beom Seok Ko; Yura Lee; Sae Byul Lee; Seunghee Baek
Journal:  Cancer Res Treat       Date:  2016-04-06       Impact factor: 4.679
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.